Platelet activation in adult HIV-infected patients on antiretroviral therapy: a systematic review and meta-analysis

Table 3 Reported markers of platelet activation in treatment-naïve and ART-treated HIV-infected patients

Effect measure	No. studies	Levels of platelet activation in PLWHIV
Effect measure	No. studies	Treatment naïve	Post-ART
sCD62P	12	Increased [6,7,8,9, 11, 21, 28, 31, 33, 41] similar between PLWHIV and controls [6]	Increased [6,7,8,9, 12, 21, 28, 29, 31]; decreased [11, 35, 40]
sCD40L	14	Increased [6,7,8, 10, 13, 30, 34, 36,37,38, 43] Similar between PLWHIV and controls [8]	Increased [7, 11, 21, 24, 27, 28, 38, 40, 46]; Increased in NNRTI-treated patients [25, 41]; Decreased in [7, 28, 37,38,39]
sGPVI	1	Increased [11]	Decreased [11]
RANTES	6	Increased [10, 29,30,31,32,33]	Increased [10, 29, 31, 45]; Decreased [26]
CD62P	3	Increased [9]	Increased [31]; Decreased In RAL-treated patients; Similar between PLWHIV and controls [6]
PMAs	2	Increased [39]	Decreased in RAL compared to NNRTI- and PI-treated PLWHIV [39]

sCD62P soluble P-selectin, sCD40L soluble CD40 Ligand, sGPVI soluble glycoprotein VI, RANTES chemokine ligand 5, CD62P P-Selectin, PMAs platelet monocyte aggregates, RAL raltegravir

ISSN: 1741-7015